Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have become standard treatments for lung cancer patients. Immune checkpoint inhibitor-related pneumonitis (CIP) was the leading cause of death among ICIs-related adverse events (irAEs). Recurrent episodes of CIP without rechallenge of ICIs were reported in several cases and maybe a unique feature of CIP. Knowledge gaps remain regarding the rate and risk factors associated to CIP's recurrence.

Methods

Data from 1,102 lung cancer patients receiving ICIs treatment between January 2016 and January 2021 were retrospectively collected and analyzed. CIP was diagnosed according to typical clinical features and/or new typical imaging changes. Recurrence of CIP (CIP-R) was defined as recurrent CIP after initial CIP improved after proper t

SUBMITTER: Tao H 

PROVIDER: S-EPMC8988083 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature